• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EPOETIN BETA Drug Record

  • Summary
  • Interactions
  • Claims
  • EPOETIN BETA chembl:CHEMBL2109092 Approved

    Alternate Names:

    RECORMON S 1000
    NEORECORMON 5000
    NEORECORMON 2000
    NEORECORMON 20000
    NEORECORMON 4000
    MAROGEN
    RECORMON S 2000
    RECORMON S 10000
    NEORECORMON 6000
    NEORECORMON 500
    NEORECORMON 10000
    NEORECORMON 3000
    RECORMON 5000
    NEORECORMON 1000
    EPOCH
    RECORMON 2000
    RECORMON S 5000
    NEORECORMON
    RECORMON 10000
    BM 06.019
    ERYTHROPOIETIN
    NEORECORMON 30000
    EPOETIN BETA
    RECORMON 1000

    Drug Info:

    Drug Indications for treatment of stroke
    Drug Indications for treatment of anemia
    FDA Approval approved
    Drug Class protein
    Drug Indications erythropoietic agent
    Drug Categories hematinics
    Drug Categories erythropoietin, genetics
    Drug Categories increased erythroid cell production
    (1 More Sources)

    Publications:

    Genc et al., 2006, Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage., Med. Hypotheses
    Kokhaei et al., 2007, Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies., Clin. Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    LaMontagne et al., 2006, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models., Mol. Cancer Ther.
    Ozüyaman et al., 2006, Adenosine produced via the CD73/ecto-5'-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight., Pflugers Arch.
    Broxmeyer et al., 1991, CD45 cell surface antigens are linked to stimulation of early human myeloid progenitor cells by interleukin 3 (IL-3), granulocyte/macrophage colony-stimulating factor (GM-CSF), a GM-CSF/IL-3 fusion protein, and mast cell growth factor (a c-kit ligand)., J. Exp. Med.
    Viviani et al., 2005, Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor., J. Neurochem.
    Tsabouri et al., 2004, Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs., J. Exp. Clin. Cancer Res.
    Hsieh et al., 2000, Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase., Blood
    Papavasiliou et al., 2006, PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin., Nephrol. Dial. Transplant.
    Bellizzi et al., 1997, Fetal proteins and chronic treatment with low-dose erythropoietin., J. Lab. Clin. Med.
    Gündüz et al., 1999, Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis., Adv Perit Dial
    Darley et al., 1997, Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells., J. Exp. Med.
    Shan et al., 1999, Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin., Blood
    Sturm et al., 2005, Recombinant human erythropoietin: effects on frataxin expression in vitro., Eur. J. Clin. Invest.
  • EPOETIN BETA   EPOR

    Interaction Score: 3.04

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Details of the Assay for Interaction Assay performed using recombinant human EPO
    Specific Action of the Ligand Agonist
    Endogenous Drug? True

    PMIDs:
    17575216 11752352 16505108


    Sources:
    TdgClinicalTrial DrugBank GuideToPharmacology

  • EPOETIN BETA   PLA2G7

    Interaction Score: 2.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16421163


    Sources:
    NCI

  • EPOETIN BETA   FXN

    Interaction Score: 2.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16269021


    Sources:
    NCI

  • EPOETIN BETA   PLAT

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10682118


    Sources:
    NCI

  • EPOETIN BETA   GSTT1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15595630


    Sources:
    NCI

  • EPOETIN BETA   AFP

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9016855


    Sources:
    NCI

  • EPOETIN BETA   CDKN1B

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11023508


    Sources:
    NCI

  • EPOETIN BETA   PTPRC

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1713254


    Sources:
    NCI

  • EPOETIN BETA   NT5E

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16468051


    Sources:
    NCI

  • EPOETIN BETA   CDKN1A

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11023508


    Sources:
    NCI

  • EPOETIN BETA   HRAS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9104820


    Sources:
    NCI

  • EPOETIN BETA   BDNF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15816864


    Sources:
    NCI

  • EPOETIN BETA   MAPK14

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10590051


    Sources:
    NCI

  • EPOETIN BETA   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16707229


    Sources:
    NCI

  • DrugBank: DB00016

    • Version: 5.1.7

    Alternate Names:
    ERYTHROPOIETIN DrugBank Drug Name
    11096-26-7 CAS Number
    Abseamed Drug Brand

    Drug Info:
    Drug Type biotech
    Drug Groups approved
    Drug Categories amino acids, peptides, and proteins

    Publications:
    Kokhaei et al., 2007, Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies., Clin. Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    LaMontagne et al., 2006, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models., Mol. Cancer Ther.

  • GuideToPharmacology: 178101620

    • Version: 29-September-2020

    Alternate Names:
    EPO Gene Symbol (for Endogenous Peptides)
    ERYTHROPOIETIN GuideToPharmacology Ligand Name

    Drug Info:
    Name of the Ligand Species (if a Peptide) Human

    Publications:

  • TdgClinicalTrial: ERYTHROPOIETIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications erythropoietic agent
    Drug Class protein
    FDA Approval approved

    Publications:

  • NCI: ERYTHROPOIETIN

    • Version: 14-September-2017

    Alternate Names:
    C477 NCI drug code

    Drug Info:

    Publications:
    Hsieh et al., 2000, Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase., Blood
    Gündüz et al., 1999, Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis., Adv Perit Dial
    Bellizzi et al., 1997, Fetal proteins and chronic treatment with low-dose erythropoietin., J. Lab. Clin. Med.

  • ChemblDrugs: chembl:CHEMBL2109092

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21